Securing America’s Generic Drug Supply: Balancing Access and Independence
This whitepaper addresses the paradox in U.S. pharmaceutical policy: while generic drugs are 90% of prescriptions and keep costs low, over 60% are made abroad. This reliance makes the supply chain vulnerable, a challenge exacerbated by the economic landscape and the Inflation Reduction Act.
The paper will explore the complexity of implementing tariffs to boost domestic manufacturing, noting that while tariffs enhance national healthcare security, they could immediately raise costs and disrupt patient access due to the low margins on generics.
The path forward requires a strategic, phased, and coordinated approach, including accessing RWD to make appropriate and innovative solutions.